News Center

Home page

Peak Report

News reports

Jianfeng Pharmaceutical has made clear its key work in the new year.

Release time:

2023-02-22

2022 held on February 19 , Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, and Huang Jinlongfen, deputy general manager of the group company and general manager of the pharmaceutical company, made arrangements for the key work of pharmaceutical company 2023 and put forward specific requirements. 2023 With the adjustment of the national epidemic control policy, the domestic into the post-epidemic period, the pharmaceutical company will focus on

to reduce the first, innovation-oriented, marketing-led, standardized and efficient " work policy, and solidly promote the production and operation management work. In terms of market expansion, the pharmaceutical industry should optimize management and business teams, strengthen process control, purify the market environment, cultivate benchmark markets, and expand Internet marketing; pharmaceutical business should give full play to regional advantages, make full use of government resources, and expand and strengthen subdivision areas; pharmaceutical retail should comply with changes in the market and customer needs, and seek breakthroughs in business philosophy and business ideas; natural products companies continue to give full play to their advantages in quality, technology, information and brand, expand new areas of the market, focus on the development of the domestic ordinary food market, maintain a steady growth in sales volume, and increase the added value of products; Shanghai Beika should find out the changing law of the pesticide market, expand the sales of pesticide products at the best price, and strive to strengthen cooperation with pharmaceutical R & D and production enterprises to achieve differentiated sales.

In terms of new drug development, continue to strengthen communication and coordination between various levels and departments; strengthen communication with drug review and approval departments to improve the speed and success rate of new drug approval; strengthen in-depth cooperation with

CRO

Company to improve new drug research and development capabilities; scientifically formulate product development plans, further clarify the responsibilities of development, production and quality departments, and accelerate the speed of new drug research and development; continue to carry out technical research, continuously optimize process parameters, improve yield, continue to introduce varieties of raw material preparation integration, stimulate the potential of API bases and preparation internationalization projects, increase the introduction and development efforts, enrich the enterprise product line. In terms of the construction and technological transformation of the project, make preparations for the international project to meet the

FDA

on-site inspection. Complete all kinds of acceptance of various construction projects and relevant approval work before putting them into production, and reach the production standard as soon as possible. Increase foreign cooperation, give full play to the advantages of production capacity and increase revenue; Continue to promote various informatization work and continuously improve the informatization and intelligence level of enterprises. In terms of cost control, further optimize the synthesis process of bulk drugs and improve the yield; Further strengthen the control of the preparation production process; Strengthen the coordination of production and marketing, optimize the production organization mode, and reasonably arrange the production cycle; Speed up the work process of photovoltaic power generation projects; Reasonable deployment of personnel to improve work efficiency; Reduce procurement costs and ensure stable supply by increasing suppliers of raw and auxiliary packaging materials.

In terms of internal control management, we will continue to improve the internal control system of the enterprise, improve the operability of the internal control system, and increase the intensity of system assessment; continue to strengthen tax planning and communicate with the tax authorities to keep abreast of policy developments and reduce the risk of tax inspection.

In terms of safety and environmental protection, take the implementation of the new safety production law as an opportunity to increase the publicity and education of laws and regulations; standardize the development of various production and business activities to ensure the safety of personnel and property. In terms of product quality,

, further strengthen self-inspection of

GMP

and GSP , discover potential quality hazards in time, and implement responsibilities; Taking the opportunity of international projects receiving US FDA certification, strengthen staff education and training, and improve professional skills and professional work ability; Attach great importance to pharmacovigilance and adverse reaction monitoring; Strengthen the construction of quality management system, further standardize quality management and quality control behavior. In terms of team building, we should attach importance to the introduction, training and use of talents, so as to provide more platforms for the growth of talents; select young cadres to enrich the management teams at all levels, enhance the vitality of the team, and create a well-trained, dedicated staff team and a United, pragmatic, responsible and capable management team, so as to meet the needs of sustainable development of enterprises. (Reporter

Ni Yingzhen)

More information

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

2020

07-30

Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise

Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has

2020

07-31

Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute

A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody

2020

07-31

The company elects a new board of directors and the board of supervisors to appoint a new management team

On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.

2020

07-31

Peak natural products pollution control results by the industry attention

As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.

2020

07-31

< 1...39 40 41...61 > 跳转到页